3M (MMM) vs ResMed (RMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
3M (MMM) has outperformed ResMed (RMD) over the past year, gaining 5.9% versus a loss of 6.0%. Over five years, MMM leads with a +21.3% price change compared with -6.2% for RMD. 3M is the larger company by market cap ($91.97 billion vs $33.14 billion), about 2.8 times the size, while ResMed is growing revenue faster (+9.9% vs +1.5%).
On valuation, ResMed trades at a lower forward P/E (17.8x vs 17.9x for 3M). 3M offers the higher dividend yield (1.72% vs 1.04%). ResMed converts more of its revenue into profit, with a net margin of 26.9% versus 13.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MMM | RMD |
|---|---|---|
| Share price | $177.99 | $235.63 |
| Market cap | $91.97B | $33.14B |
| 1-day change | -0.27% | -0.53% |
| YTD return | +11.17% | -2.18% |
| 1-year return | +5.89% | -6.03% |
| 5-year return | +21.28% | -6.20% |
| P/E ratio (TTM) | 26.57 | 21.46 |
| Forward P/E | 17.94 | 17.82 |
| EPS (TTM) | $6.70 | $10.98 |
| Dividend yield | 1.72% | 1.04% |
| Annual dividend | $3.07 | $2.46 |
| Revenue (latest FY) | $24.95B | $5.65B |
| Revenue growth (YoY) | +1.52% | +9.85% |
| Net income (latest FY) | $3.25B | $1.52B |
| Gross margin | 39.91% | 61.06% |
| Operating margin | 18.55% | 33.37% |
| Net margin | 13.03% | 26.94% |
| 52-week high | $196.90 | $277.67 |
| 52-week low | $139.34 | $180.27 |
| Distance from 52-week high | -9.60% | -15.14% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +9.00% | +12.18% |
| Average volume | 3.28M | 1.30M |
| Shares outstanding | 516.73M | 140.66M |
| Employees | 60,500 | 11,370 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- 3M is about 2.8 times larger than ResMed by market value ($91.97B vs $33.14B).
- MMM has outperformed RMD by 11.9 percentage points over the past year.
- ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus 13.0 cents for 3M.
- ResMed grew revenue faster in its latest fiscal year (+9.85% vs +1.52%).
About 3M
MMM stock →3M Company provides diversified technology services in the America, the Asia Pacific, Europe, the Middle East, Africa, and internationally. It operates through three segments: Safety and Industrial, Transportation and Electronics, and Consumer.
Health Care · Medical/Dental Instruments · 60,500 employees
About ResMed
RMD stock →ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
Health Care · Medical/Dental Instruments · 11,370 employees
MMM vs RMD FAQ
Which is bigger, 3M or ResMed?
3M (MMM) is larger, with a market capitalization of $91.97B compared with $33.14B for ResMed (RMD).
Which stock has performed better over the past year, MMM or RMD?
MMM returned +5.89% over the past 12 months, compared with -6.03% for RMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, MMM or RMD?
RMD has the lower trailing P/E at 21.5, versus 26.6 for MMM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, 3M or ResMed?
3M has the higher yield at 1.72%, compared with 1.04% for ResMed.
Are 3M and ResMed in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.